Evidence map›Paper›PMID 40809139›Full record

ArticleFrontiers in systems biology2024

PdPANA: phagemid display as peptide array for neutralizing antibodies, an engineered

Javier Uzcátegui, Khaleel Mullah, Daniel Buvat de Virgini, Andrés Mendoza, Rafael Urdaneta, Alejandra Naranjo

Abstract read
In one paragraph

Article in Frontiers in systems biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Javier UzcáteguiLaboratorio de Inmunopatología, Centro de Medicina Experimental, Instituto Venezolano de Investigaciones Científicas, Miranda, Venezuela.
Khaleel MullahLaboratorio de Microbiología Molecular y Biotecnología, Facultad de Ciencias, Universidad de Los Andes, Mérida, Venezuela.
Daniel Buvat de VirginiLaboratorio de Enfermedades Zoonóticas y Metaxénicas Bacterianas, Coordinación de Bacteriología, Instituto Nacional de Higiene "Rafael Rangel", Distrito Capital, Venezuela.
Andrés MendozaIndependent Researcher, Distrito Capital, Venezuela.
Rafael UrdanetaLaboratorio de Biología y Medicina Experimental, Facultad de Ciencias, Universidad de Los Andes, Mérida, Venezuela.
Alejandra NaranjoIndependent Researcher, Ontario, CA, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has tested the technical, scientific, and industrial resources of all countries worldwide. Faced with the absence of pharmacological strategies against the disease, an effective plan for vaccinating against SARS-CoV-2 has been essential. Due to the lack of production means and necessary infrastructure, only a few nations could adequately confront this pathogen with a production, storage, and distribution scheme in place. This disease has become endemic in many countries, especially in those that are developing, thus necessitating solutions tailored to their reality. In this paper, we propose an

Indexed as

COVID-19immunoinformaticsPdPANAphage-displaySARS-CoV-2vaccine design

Identifiers

PMID40809139
PMCPMC12341989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.